UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

Headache, 2020-07, Vol.60 (7), p.1259-1272

2020

Volltextzugriff (PDF)

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Journal of headache and pain, 2018-02, Vol.19 (1), p.13-12, Article 13

2018

Volltextzugriff (PDF)

Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)

Headache, 2013-04, Vol.53 (4), p.644-655

2013

Volltextzugriff (PDF)

Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study

BMC neurology, 2022-03, Vol.22 (1), p.72-72, Article 72

2022

Volltextzugriff (PDF)

Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment

Journal of primary care & community health, 2020, Vol.11, p.215013272095993-2150132720959935

Blumenfeld, Andrew M.

2020

Volltextzugriff (PDF)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine

Headache, 2022-01, Vol.62 (1), p.106-108

2022

Volltextzugriff (PDF)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review

Neurology and therapy, 2023-10, Vol.12 (5), p.1533-1551

2023

Volltextzugriff (PDF)

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

Journal of headache and pain, 2019-02, Vol.20 (1), p.12-12, Article 12

2019

Volltextzugriff (PDF)

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Journal of headache and pain, 2019-01, Vol.20 (1), p.10-10, Article 10

2019

Volltextzugriff (PDF)

Lasmiditan mechanism of action – review of a selective 5-HT1F agonist

Journal of headache and pain, 2020-06, Vol.21 (1), p.71-13, Article 71

2020

Volltextzugriff (PDF)

Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine

Headache, 2008-02, Vol.48 (2), p.210-220

2008

Volltextzugriff (PDF)

Injection technique of the upper face with onabotulinumtoxinA in chronic migraine

Headache, 2023-07, Vol.63 (7), p.849-860

2023

Volltextzugriff (PDF)

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

Journal of primary care & community health, 2020, Vol.11, p.215013272095993-2150132720959936

2020

Volltextzugriff (PDF)

Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey

Headache, 2016-02, Vol.56 (2), p.306-322

2016

Volltextzugriff (PDF)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

Headache, 2019-11, Vol.59 (10), p.1700-1713

2019

Volltextzugriff (PDF)

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Cephalalgia, 2021-08, Vol.41 (9), p.979-990

2021

Volltextzugriff (PDF)

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Headache, 2021-04, Vol.61 (4), p.642-652

2021

Volltextzugriff (PDF)

Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine

The Journal of family practice, 2020-01, Vol.69 (1 Suppl), p.S8

2020

Volltextzugriff (PDF)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial

Headache, 2023-01, Vol.63 (1), p.79-88

2023

Volltextzugriff (PDF)

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

Pain and therapy, 2021-12, Vol.10 (2), p.809-826

2021

Volltextzugriff (PDF)

Response to “Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice”

Headache, 2020-11, Vol.60 (10), p.2597-2599

2020

Volltextzugriff (PDF)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Neurology, 2023-02, Vol.100 (8), p.e764

2023

Volltextzugriff (PDF)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

Headache, 2022-02, Vol.62 (2), p.198-207

2022

Volltextzugriff (PDF)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety

Journal of neurology, neurosurgery and psychiatry, 2019-03, Vol.90 (3), p.353-360

2019

Volltextzugriff (PDF)

Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine

Headache, 2023-03, Vol.63 (3), p.322-332

2023

Volltextzugriff (PDF)

1 – 25 von 124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(123)
Bücher
(1)

Sprache

Englisch
(124)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(78)
Humans
(72)
Neurosciences & Neurology
(55)
Clinical Neurology
(53)
Migraine
(47)
Female
(41)
Adult
(39)
Male
(37)
Migraine Disorders - Drug Therapy
(33)
Headache
(26)
Middle Aged
(26)
Treatment Outcome
(24)
Chronic Disease
(18)
Double-Blind Method
(18)
Neurosciences
(17)
Migraine Disorders - Prevention & Control
(16)
Aged
(15)
Chronic Migraine
(15)
Headaches
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)

Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study

Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Lasmiditan mechanism of action – review of a selective 5-HT1F agonist

Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine

Injection technique of the upper face with onabotulinumtoxinA in chronic migraine

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

Response to “Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice”

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety

Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine

Suchergebnisse filtern